- Anti-IgA antibodies have been identified in severely IgA deficient patients who experienced infusion reactions to blood products containing small amounts of IgA, typically in plasma, including the following: whole blood, RBCs, plts, FFP, cryoprecipitate, granulocytes, IVIG
- It is suggested that screening for anti-IgA antibodies in all patients with severe IgA deficiency and for patients with partial IgA deficiency who have received blood products in the past and experienced an infusion reaction.
- In patients who have anti-IgA antibodies, it is suggested that repeat testing be done before each administration of plasma-containing blood products (except immune globulin).
- All blood products should be used with caution in IgA deficient patients, and appropriate staff and medication should be available to treat anaphylaxis
- Patients can receive cells that have been washed to remove as much of the contaminating IgA as possible
- Desensitization to blood products is another management approach that may be appropriate in specific circumstances
IgA deficiency: Transfusion risk